黛力新辅助治疗心内科患者躯体化障碍的临床观察

The clinical observation of Deanxit in the adjunctive therapy of patients with somatization disorder in department of cardiology

目的观察黛力新辅助治疗心内科患者躯体化障碍的临床疗效。方法将103例躯体化障碍患者随机分为对照组和黛力新治疗组，其中对照组51例，黛力新治疗组52例，对照组给予倍他乐克23．75—95mg／d（每片47．5mg，剂量视心率情况而定），口服，并加用谷维素30mg，3次／日，口服；黛力新组倍他乐克用量与对照组相同，并加用黛力新片，早晨、中午各服1片，观察其症状改善情况及躯体化症状自评量表评分变化。结果黛力新治疗组在治疗第8周后躯体化症状自评量表平均评分明显低于对照组，治疗总有效率为92．31％，明显高于对照组41．17％（P〈0．05）。结论黛力新是辅助治疗心内科躯体化障碍患者的一种效果肯定且安全的药物。

Objective To observe the clinical efficacy of Deanxit in the adjunctive therapy of patients with somatization disorder in department of cardiology. Methods A total of 103 patients with somatization disorder were randomly divided into the control group （51 patients） and Dcanxit treatment group（52 patients）. Metoprolol （23.75-95.00 mg/d,47.5 mg per tablet） and oryzanol（30 mg three times a clay） were given to the patients of the control group. The dose of Metoprolol was decided according to the patients＇ heart rates. Deanxit was used in the patients of Deanxit treatment group besides the same dose of Metoprolol, and one tablet was supplied in morning and midday respectively. We observed the improvements of symptoms and the change of somatic self-rating scale （SSS） scores. Results The average SSS scores of Deanxit treatment group were significantly lower than those of control group after 8 weeks. The efficiency of Deanxit treatment group was 92.31% , higher than that of control group （41.17 % , P 〈 0.05 ） after 8 weeks. Conclution Deanxit is effective and safe in the adjunctive therapy of patients with somati- zation disorder in department of cardiology.